| LISATA THERAPEUTICS |
| USA |
| Gesundheit |
| US1280583022 / A3DWGC |
| 8NE (Frankfurt) / LSTA (NASDAQ) |
| FRA:8NE, ETR:8NE, 8NE:GR, NASDAQ:LSTA |
| - |
| https://www.lisata.com/ |
|
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other major diseases. The company’s lead product candidate, certepetide, is designed to activate a novel uptake pathw..
>Volltext.. |
| 12.18 Mio. EUR |
| 2.81 Mio. EUR |
| 0.09 Mio. EUR |
| -14.18 Mio. EUR |
| -12.67 Mio. EUR |
| -1.42 EUR |
| - |
| 9.05 Mio. EUR |
| -10.68 Mio. EUR |
| 3.5 |
| -90.36% |
| 20.3% |
| - |
| - |
| - |
| - |
| LISATA |
| 17.09.26 |
|